Figure 1.
Flow chart of patients in this study. In cohort 1, liver-related death-free survival and HCC-free survival were evaluated in patients with AIH. In cohort 2, the efficacy of serum biomarkers for predicting long-term prognosis was evaluated in patients with AIH. AIH, autoimmune hepatitis; HCC, hepatocellular carcinoma.
